VOGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Vogenx, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 17, 2026
$15.92+1.39 (+9.57%)
Close on Oct 19, 2026
- Market cap
- $86.79M
- P/E (TTM)
- –
- Dividend yield
- –
About Vogenx
Pharmaceutical Preparations, SIC 2834
Vogenx, Inc. is listed on Nasdaq under the ticker VOGX, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Vogenx, Inc.
- Headquarters
- Raleigh, NC
- Address
- 3901 Barrett Drive, Suite 300 27609
- Phone
- (919) 659-5677
- Website
- vogenx.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- VOGX
- Exchange
- Nasdaq
- IPO date
- Aug 12, 2026
- Shares outstanding
- 15M, Sep 17, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1903784
- CUSIP
- 92859A106
- ISIN
- US92859A1060
- LEI
- 5299004KM33YCDWS6I69
- EIN
- 86-3697324
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Steven R. Delmar | Chief Financial Officer, Director | 704,273 |
| James Green | Chief Executive Officer, Director | 1,800,000 |
| William Wilkison | Chief Scientific Officer, Director | 1,800,000 |
| Kenneth John Toombs | Director | – |
| Peter Pieraccini | Director | 42,735 |
| Timothy Boris | Director | – |
| Richard M. Gorman | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 12, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 10, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |